🇺🇸 FDA
Patent

US 7396918

IGF-I fusion polypeptides and therapeutic uses thereof

granted A61KA61K38/30A61P

Quick answer

US patent 7396918 (IGF-I fusion polypeptides and therapeutic uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jul 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jul 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K38/30, A61P, A61P19/10, A61P21/00